Physiological implications of adenosine receptor-mediated platelet aggregation

Journal of Cellular Physiology

Volumn 226, Issue 1, 2011, Pages 46-51

  Johnston Cox, Hillary A ^a   Yang, Dan ^a   Ravid, Katya ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE DIPHOSPHATE; ADENOSINE RECEPTOR; BX 667; CANGRELOR; CLOPIDOGREL; CYCLIC AMP; G PROTEIN COUPLED ADENOSINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; JF 959602; PRASUGREL; PRT 060128; PURINERGIC P2Y1 RECEPTOR; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG;

BLOOD VESSEL INJURY; CELL SURFACE; HUMAN; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS; UPREGULATION;

ADENOSINE; ANIMALS; CYCLIC AMP; GENE EXPRESSION REGULATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P1;

EID: 78049288621     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22379     Document Type: Review

References (62)

1. Amisten S, Braun OO, Bengtsson A, Erlinge D. 2008. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 122: 47-57.
2. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB. 2003. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112: 398-406.
3. Andreotti F, Pasceri V. 1996. Ischaemic preconditioning. Lancet 348: 204.
4. Biaggioni I, Paul S, Puckett A, Arzubiaga C. 1991. Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 258: 588-593.
5. Born GV, Cross MJ. 1964. Effects of inorganic ions and of plasma proteins on the aggregation of blood platelets by adenosine diphosphate. J Physiol 170: 397-414.
6. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. 2006. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112: 358-404.
7. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. 2007. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153: 66, e69-16.
8. Brass LF. 2003. Thrombin and platelet activation. Chest 124: 18S-25S.
9. Brass LF, Manning DR, Cichowski K, Abrams CS. 1997. Signaling through G proteins in platelets: To the integrins and beyond. Thromb Haemost 78: 581-589.
10. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF. 2007. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50: 1844-1851.
11. Chen M, Stracher A. 1989. In situ phosphorylation of platelet actin-binding protein by cAMP-dependent protein kinase stabilizes it against proteolysis by calpain. J Biol Chem 264: 14282-14289.
12. Cooper JA, Hill SJ, Alexander SP, Rubin PC, Horn EH. 1995. Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets. Br J Clin Pharmacol 40: 43-50.
13. Doni MG, Deana R, Bertoncello S, Zoccarato F, Alexandre A. 1988. Forskolin and prostacyclin inhibit fluoride induced platelet activation and protein kinase C-dependent responses. Biochem Biophys Res Commun 156: 1316-1323.
14. Eckle T, Grenz A, Laucher S, Eltzschig HK. 2008. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118: 3301-3315.
15. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ. 2007. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35: 1096-1104.
16. Fredholm BB. 2007. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14: 1315-1323.
17. Gachet C. 2001a. ADP receptors of platelets and their inhibition. Thromb Haemost 86: 222-232.
18. Gachet C. 2001b. Identification, characterization, and inhibition of the platelet ADP receptors. Int J Hematol 74: 375-381.
19. Gachet C. 2008. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99: 466-472.
20. Gachet C, Leon C, Hechler B. 2006. The platelet P2 receptors in arterial thrombosis. Blood Cells Mol Dis 36: 223-227.
21. Gino van Heeke RS, Metais J-Y, Fozard JR, Stephen G, Amanda W, Jane D, Hall IP. 2003. Single nucleotide polymorphism analysis of the human adenosine A2B receptor gene: Prevalence of SNPs in asthmatics and normal subjects. Gene Funct Dis 3: 87-92.
22. Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD. 2006. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151: 689, e681-689, e610.
23. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, Eltzschig HK. 2008. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 5: e137.
24. Haslam RJ, Rosson GM. 1975. Effects of adenosine on levels of adenosine cyclic 3', 5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 11: 528-544.
25. Hata K, Whittaker P, Kloner RA, Przyklenk K. 1999. Brief myocardial ischemia attenuates platelet thrombosis in remote, damaged, and stenotic carotid arteries. Circulation 100: 843-848.
26. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. 1998. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood 92: 152-159.
27. Hettasch JM, Sellers JR. 1991. Caldesmon phosphorylation in intact human platelets by cAMP-dependent protein kinase and protein kinase C. J Biol Chem 266: 11876-11881.
28. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. 2006. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 27: 1038-1047.
29. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH, Robson SC. 1996. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271: 33116-33122.
30. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. 2006. Nucleotide receptor signaling in platelets. J Thromb Haemost 4: 2317-2326.
31. Kolachala V, Asamoah V, Wang L, Obertone TS, Ziegler TR, Merlin D, Sitaraman SV. 2005. TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: A basis for A2bR overexpression in colitis. Cell Mol Life Sci 62: 2647-2657.
32. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP. 2006. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 20: 2242-2250.
33. Krotz F, Sohn HY, Klauss V. 2008. Antiplatelet drugs in cardiological practice: Established strategies and new developments. Vasc Health Risk Manage 4: 637-645.
34. Lam P, Hong CJ, Tsai SJ. 2005. Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci Lett 378: 98-101.
35. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M. 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388: 674-678.
36. Linden J. 2005. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67: 1385-1387.
37. Linden MD, Barnard MR, Frelinger AL, Michelson AD, Przyklenk K. 2008. Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: Differences between canine and human models. Thromb Res 121: 689-698.
38. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. 2005. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 31: 184-194.
39. Offermanns S. 2006. Activation of platelet function through G protein-coupled receptors. Circ Res 99: 1293-1304.
40. Paul S, Feoktistov I, Hollister AS, Robertson D, Biaggioni I. 1990. Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: Evidence that both effects are coupled to adenylate cyclase. Mol Pharmacol 37: 870-875.
41. Payne CD, Li YG, Small DS, Ernest CS II, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ. 2007. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 50: 555-562.
42. Pfefferkorn JA, Choi C, Winters T, Kennedy R, Chi L, Perrin LA, Lu G, Ping YW, McClanahan T, Schroeder R, Leininger MT, Geyer A, Schefzick S, Atherton J. 2008. P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett 18: 3338-3343.
43. Przyklenk K, Whittaker P. 2000. Brief antecedent ischemia enhances recombinant tissue plasminogen activator-induced coronary thrombolysis by adenosine-mediated mechanism. Circulation 102: 88-95.
44. Przyklenk K, Whittaker P. 2005. In vitro platelet responsiveness to adenosine-mediated "preconditioning" is age-dependent. J Thromb Thrombolysis 19: 5-10.
45. Purvis JE, Chatterjee MS, Brass LF, Diamond SL. 2008. A molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 activation. Blood 112: 4069-4079.
46. Raju NC, Eikelboom JW, Hirsh J. 2008. Platelet ADP-receptor antagonists for cardiovascular disease: Past, present and future. Nat Clin Pract Cardiovasc Med 5: 766-780.
47. Riondino S, Lotti LV, Cutini L, Pulcinelli FM. 2005. Collagen-induced platelet shape change is not affected by positive feedback pathway inhibitors and cAMP-elevating agents. J Biol Chem 280: 6504-6510.
48. Rump LC, Bohmann C, Schwertfeger E, Krumme B, von Kugelgen I, Schollmeyer P. 1996. Extracellular ATP in the human kidney: Mode of release and vascular effects. J Auton Pharmacol 16: 371-375.
49. Sauer H, Hescheler J, Wartenberg M. 2000. Mechanical strain-induced Ca(2+) waves are propagated via ATP release and purinergic receptor activation. Am J Physiol Cell Physiol 279: C295-C307.
50. Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP. 2006. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 4: 638-647.
51. Shattil SJ, Kashiwagi H, Pampori N. 1998. Integrin signaling: The platelet paradigm. Blood 91: 2645-2657.
52. Sim DS, Merrill-Skoloff G, Furie BC, Furie B, Flaumenhaft R. 2004. Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels. Blood 103: 2127-2134.
53. St Hilaire C, Koupenova M, Carroll SH, Smith BD, Ravid K. 2008. TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. Biochem Biophys Res Commun 375: 292-296.
54. Storey RF, Oldroyd KG, Wilcox RG. 2001. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85: 401-407.
55. Van der Wijk T, De Jonge HR, Tilly BC. 1999. Osmotic cell swelling-induced ATP release mediates the activation of extracellular signal-regulated protein kinase (Erk)-1/2 but not the activation of osmo-sensitive anion channels. Biochem J 343: 579-586.
56. Varani K, Portaluppi F, Gessi S, Merighi S, Ongini E, Belardinelli L, Borea PA. 2000. Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors: Functional and biochemical aspects. Circulation 102: 285-289.
57. 2+)-apyrase. J Biol Chem 271: 9898-9901.
58. White JG. 1968. Fine structural alterations induced in platelets by adenosine diphosphate. Blood 31: 604-622.
59. Yaar R, Jones MR, Chen JF, Ravid K. 2005. Animal models for the study of adenosine receptor function. J Cell Physiol 202: 9-20.
60. Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM, Ravid K. 2008. The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci USA 105: 792-796.
61. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K. 2010. A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 8: 817-827.
62. Zhang W, Colman RW. 2007. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A. Blood 110: 1475-1482.